Affinity Asset Advisors LLC Has $28.99 Million Stock Holdings in Lexeo Therapeutics, Inc. $LXEO

Affinity Asset Advisors LLC lifted its position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) by 57.8% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 5,050,211 shares of the company’s stock after purchasing an additional 1,850,211 shares during the quarter. Lexeo Therapeutics accounts for approximately 1.5% of Affinity Asset Advisors LLC’s holdings, making the stock its 20th biggest holding. Affinity Asset Advisors LLC owned approximately 0.06% of Lexeo Therapeutics worth $28,988,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. RA Capital Management L.P. acquired a new position in Lexeo Therapeutics in the fourth quarter valued at about $49,650,000. Paradigm Biocapital Advisors LP bought a new stake in Lexeo Therapeutics during the 4th quarter worth about $47,299,000. Balyasny Asset Management L.P. acquired a new stake in Lexeo Therapeutics in the 2nd quarter valued at about $16,117,000. Avoro Capital Advisors LLC acquired a new stake in Lexeo Therapeutics in the 4th quarter valued at about $32,769,000. Finally, State Street Corp raised its stake in shares of Lexeo Therapeutics by 485.1% in the fourth quarter. State Street Corp now owns 3,187,722 shares of the company’s stock worth $31,654,000 after acquiring an additional 2,642,877 shares during the last quarter. Institutional investors and hedge funds own 60.67% of the company’s stock.

Insider Buying and Selling at Lexeo Therapeutics

In other Lexeo Therapeutics news, insider Narinder Pal Bhalla sold 22,306 shares of Lexeo Therapeutics stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $4.42, for a total transaction of $98,592.52. Following the transaction, the insider directly owned 82,194 shares in the company, valued at approximately $363,297.48. The trade was a 21.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Richard Nolan Townsend sold 25,947 shares of the business’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $4.48, for a total value of $116,242.56. Following the completion of the transaction, the chief executive officer directly owned 377,817 shares of the company’s stock, valued at approximately $1,692,620.16. The trade was a 6.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 62,204 shares of company stock valued at $280,089 in the last three months. 2.00% of the stock is owned by company insiders.

Lexeo Therapeutics Price Performance

Lexeo Therapeutics stock opened at $4.66 on Friday. The company’s 50 day simple moving average is $4.75 and its 200 day simple moving average is $6.02. Lexeo Therapeutics, Inc. has a fifty-two week low of $3.60 and a fifty-two week high of $10.99. The firm has a market capitalization of $365.91 million, a price-to-earnings ratio of -3.21 and a beta of 1.42.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its earnings results on Monday, May 11th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.04. As a group, analysts predict that Lexeo Therapeutics, Inc. will post -1.21 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. JPMorgan Chase & Co. reduced their target price on shares of Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating on the stock in a research report on Thursday, June 25th. Wall Street Zen raised Lexeo Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings raised Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 10th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $17.00 price target on shares of Lexeo Therapeutics in a research note on Monday, May 11th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $18.75.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.